P139 OLORINAB, A PERIPHERALLY RESTRICTED, HIGHLY SELECTIVE AGONIST OF THE CANNABINOID RECEPTOR TYPE 2 FOR THE MANAGEMENT OF VISCERAL PAIN IN INFLAMMATORY BOWEL DISEASE (IBD) – PRECLINICAL AND EARLY CLINICAL DEVELOPMENT

Beatriz F. Lindstrom, Jon L. Ruckle, Stewart A. Turner, Kathe Stauber, Stuart M. Brierley, Brett A. English, Bruce Yacyshyn

Research output: Contribution to journalArticle

Original languageEnglish
Pages (from-to)S92-S93
JournalGastroenterology
Volume156
Issue number3
DOIs
Publication statusPublished - Feb 2019

Cite this